Vaxcyte to Present at Key Investor Conferences in Early September
Event summary
- Vaxcyte to participate in Wells Fargo Healthcare Conference (Sept 8) and Cantor Global Healthcare Conference (Sept 9)
- Fireside chats scheduled for both events, with live webcasts available for 30 days post-conference
- Company developing VAX-31 (31-valent pneumococcal vaccine) and VAX-24 (24-valent pneumococcal vaccine)
- VAX-A1 (Group A Strep vaccine) in Phase 1 clinical trials
- Vaxcyte uses XpressCF® cell-free protein synthesis platform licensed from Sutro Biopharma
The big picture
Vaxcyte's participation in major investor conferences comes as the company advances its pneumococcal and Group A Strep vaccine candidates. The biotech sector is increasingly focused on next-generation vaccines, particularly those addressing antibiotic-resistant strains. Vaxcyte's XpressCF® platform positions it uniquely in the space, but competition remains fierce. Investors will be watching for updates on clinical trial progress and potential regulatory milestones.
What we're watching
- Clinical Progress
- How VAX-31 and VAX-24 Phase 3 and Phase 2 trials progress and whether they meet key endpoints.
- Market Positioning
- Whether Vaxcyte can differentiate itself in the competitive pneumococcal vaccine market.
- Investor Sentiment
- The reception of Vaxcyte's pipeline updates and strategic direction at upcoming investor conferences.
Related topics